醫藥股普遍造好 藥明系揚6%-8% 科倫博泰漲逾7%創上市新高
恆指現報16,599,升99點或0.6%,總成交額565億元。
醫藥股今天普遍造好。聖諾醫藥-B(02257.HK)最高見9.84元,現報9.34元,急升17%,重越10天線(8.9元)。
美國《生物安全法案》發起人邁克·加拉格爾於上周五突然宣布辭職,或給法案帶來變數。藥明系今早全面反彈,藍籌藥明康德(02359.HK)及藥明生物(02269.HK)高見40.15元及14.28元,現報39.8元及14.08元,回升7.4%及8%;藥明合聯(02268.HK)高見19.2元,現報18.94元,回升5.8%。
和黃醫藥(00013.HK)治療溶血性貧血藥物在中國啟動研究註冊階段,該股重越10天線(27.3元),最高見27.85元,現報27.4元,回升4.8%。
信達生物(01801.HK)獲摩通升目標價至51元,評級「增持」,該股今早挑戰50天及250線(37.96元及38.1元),最高見38.15元,現報38.1元,回升5.8%。
科倫博泰生物-B(06990.HK)反覆連升第五天,最低見157.2元獲承接,掉頭升破月中所創上市高位(175元),最高見177.9元,現報176.2元,反覆續升7.6%。
君聖泰醫藥-B(02511.HK)由紀錄低位反彈,最高見6.65元,現報6.25元,回升33.1%。榮昌生物(09995.HK)重越10天線,最高見28.1元,現報28.05元,回升4.7%。宜明昂科-B(01541.HK)反覆重越10天線,現報16.68元,升約3%。
樂普生物-B(02157.HK)、三葉草生物-B(02197.HK)、藍籌翰森(03692.HK)、康龍化成(03759.HK)、艾美疫苗(06660.HK)、金斯瑞(01548.HK)、康方生物(09926.HK)及騰盛博藥-B(02137.HK)升約2%-4%
然而,上周三才以每股19.8元上市的荃信生物-B(02509.HK)回吐5%報19.9元。維亞生物(01873.HK)續跌5.2%報0.55元(剛為10天線)。百心安-B(02185.HK)續跌4.2%報2.3元。綠葉製藥(02186.HK)、開拓藥業-B(9939.HK)及四環醫藥(00460.HK)跌1%-1.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.